Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?
Septerna, a clinical-stage biotech focused on GPCR-targeted therapies, reported significant insider selling in its latest SEC filing.
Overview
Samira Shaikhly, Chief People Officer of Septerna (NASDAQ:SEPN), reported the exercise and immediate sale of 11,798 shares of Common Stock for a transaction value of approximately $355,000, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($30.06); post-transaction value based on May 26, 2026 market close.
Details
Septerna is a clinical-stage biotechnology company specializing in the discovery and development of GPCR-targeted oral therapies for complex diseases.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.